Clinical trial
Monotherapy With Levetiracetam in Patients Suffering From Epilepsy.
NCT00150813 · UCB Pharma SA, Industry · Completed
Key facts
| NCT number | NCT00150813 |
|---|---|
| Title | Monotherapy With Levetiracetam in Patients Suffering From Epilepsy. |
| Official title | A Multicenter, Open-label, Follow-up Trial Evaluating the Long-term Safety of Levetiracetam Individualized Dose From 1000 to 3000 mg/Day (Oral Tablets of 500 mg b.i.d.), Used as Monotherapy in Subjects (≥ 16 Years) Suffering From Epilepsy and Coming From the N01061 or the N01093 Trials. |
| Lead sponsor | UCB Pharma SA, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Epilepsy, Tonic-clonic |
| Intervention type | Drug |
| Interventions | Levetiracetam |
| Enrollment | 66 |
| Start date | Aug 10, 2005 |
| Primary completion | May 29, 2007 |
| Completion | May 29, 2007 |
| First posted | Sep 8, 2005 |
| Last update posted | Nov 21, 2018 |
| Countries | Czechia, Hungary, Poland, Sweden |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: